332 related articles for article (PubMed ID: 27208498)
21. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
Newcomer JW; Eriksson H; Zhang P; Meehan SR; Weiss C
J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31577867
[TBL] [Abstract][Full Text] [Related]
22. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
Fava M; Ménard F; Davidsen CK; Baker RA
J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
[TBL] [Abstract][Full Text] [Related]
23. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
24. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
25. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
Lepola U; Hefting N; Zhang D; Hobart M
Int J Geriatr Psychiatry; 2018 Oct; 33(10):1403-1410. PubMed ID: 30039634
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies.
Katzman MA; Therrien F; MacKenzie EM; Wang F; de Jong-Laird A; Boucher M
J Affect Disord; 2022 Nov; 316():201-208. PubMed ID: 35970327
[TBL] [Abstract][Full Text] [Related]
27. Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data.
McIntyre RS; Therrien F; Ismail Z; Meehan SR; Miguelez M; Larsen KG; Chen D; MacKenzie EM; Thase ME
J Psychiatr Res; 2023 Jun; 162():71-78. PubMed ID: 37099968
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
29. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.
Hobart M; Zhang P; Skuban A; Brewer C; Hefting N; Sanchez R; McQuade RD
J Clin Psychopharmacol; 2019; 39(3):203-209. PubMed ID: 30946704
[TBL] [Abstract][Full Text] [Related]
30. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4.
Therrien F; Ward C; Chokka P; Habert J; Ismail Z; McIntyre RS; MacKenzie EM
Can J Psychiatry; 2024 Jul; 69(7):513-523. PubMed ID: 38425284
[TBL] [Abstract][Full Text] [Related]
31. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
[TBL] [Abstract][Full Text] [Related]
32. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Earley WR; Guo H; Németh G; Harsányi J; Thase ME
Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
[TBL] [Abstract][Full Text] [Related]
33. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
[TBL] [Abstract][Full Text] [Related]
35. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
Nelson JC; Rahman Z; Laubmeier KK; Eudicone JM; McQuade RD; Berman RM; Marcus RN; Baker RA; Sheehan JJ
CNS Spectr; 2014 Dec; 19(6):528-34. PubMed ID: 24642260
[TBL] [Abstract][Full Text] [Related]
37. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
Kane JM; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
[TBL] [Abstract][Full Text] [Related]
39. Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder.
Clayton AH; Ivkovic J; Chen D; George V; Hobart M
J Clin Psychopharmacol; 2020; 40(6):560-567. PubMed ID: 33136923
[TBL] [Abstract][Full Text] [Related]
40. Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Yoon S; Jeon SW; Ko YH; Patkar AA; Masand PS; Pae CU; Han C
J Clin Psychopharmacol; 2017 Feb; 37(1):46-53. PubMed ID: 27941419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
